The Food and Drug Administration said Friday it approved a new drug from Boehringer Ingelheim for patients with a genetic variant of advanced lung cancer.

The agency said it approved the company's Gilotrif for lung cancer patients that test positive for certain gene mutations in their tumors. The agency approved the drug alongside a diagnostic test from Qiagen NV designed to detect the mutation. The test detects epidermal growth factor receptor abnormalities found in roughly 10 percent of patients with the most prevalent form of lung cancer, known as non-small cell lung cancer.

Lung cancer is the deadliest form of cancer among men and women in the U. S. and is expected to kill nearly 160,000 people this year, according to the National Cancer Institute.

The FDA specifically approved the drug for untreated cancer that has spread from the lungs.

"The approval of companion diagnostic tests and drugs are important developments in oncology, as they help us bring safe and effective treatments to patients who need them," said Alberto Gutierrez, FDA's director of in vitro diagnostics.

Shares of Netherlands-based Qiagen NV rose 73 cents, or 3.8 percent, to $20.68 in trading. Boehringer Ingelheim is based in Germany.

About News.net

Publishing Services International Limited (PSIL) is the publisher and operator of a worldwide network of online news sites dedicated to delivering fair, accurate and relevant reporting from a variety of the world’s most trusted sources – from the biggest cities to the smallest towns.

We deliver positive and powerful messages to our readers, providing up‑to‑the‑second news that matters to the individual.

Our promise is to serve communities and individuals worldwide, delivering information that hasn’t always been available to them. We will give them back a voice – a voice that’s empowering because it is theirs – and provide a platform to communicate between themselves and the world.

We believe people are not just generic demographics; they are individuals with their own preferences and curiosities. We are about understanding these individuals, listening to them, and serving them.

We are the new pioneering spirit of news – we’re not talking to everyone, we’re talking with every one.

If you want your news, your voice, your way, on your time – we’ve got news for you.

 

FAQs

Email

If you have any questions or concerns please email us on support@news.net

Phone

  • Australia, Toll Free 1-800-983-421
  • Hong Kong, Toll Free 800-906-187
  • Singapore, Toll Free 800-852-3871
  • USA/Canada, Toll Free 1-800-830-4132

Advertise With Us

Interested in being awesome?
Contact us by email or phone.

Cancel